Bafna Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE878I01022
NSEID: BAFNAPH
BSEID: 532989

INR

149.65

1.65 (1.11%)

BSENSE

Dec 19

BSE+NSE Vol: 29.09 k

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "149.65",
    "chg": 1.65,
    "chgp": "1.11%",
    "dir": 1,
    "prev_price": "148.00",
    "mcapval": "350.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE878I01022",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "29.09 k",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Bafna Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bafna-pharma-fallingrising-3755725",
        "imagepath": "",
        "date": "2025-12-11 00:47:43",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Bafna Pharmaceuticals has experienced a notable downturn over the past week, with its stock price falling by 7.68%, significantly underperforming the broader Sensex index, which declined by only 0.84% during the same period. This recent weakness contrasts sharply with the company’s impressive year-to-date gains of 83.92%, far outpacing the Sensex’s 8.00% rise. Over the last year, the stock has also delivered a robust 75.87% return, compared to the Sensex’s modest 3.53% increase. However, the one-month performance reveals a steep 26.85% decline, indicating a period of correction or profit-taking by investors.</p>\n<p><strong>Technical Indicators and Trading Patterns</strong></p>\n<p>The stock’s technical profile suggests a mixed outlook. ..."
      },
      {
        "title": "Bafna Pharma. Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3749783",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharma_mojoScore_3749783.png",
        "date": "2025-12-06 10:10:33",
        "description": "Bafna Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by strong stock returns but tempered by concerns over valuation and fundamental quality metrics."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3749115",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3749115.png",
        "date": "2025-12-05 14:36:39",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3744340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3744340.png",
        "date": "2025-12-03 13:35:44",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3741826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3741826.png",
        "date": "2025-12-02 13:20:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment."
      },
      {
        "title": "How has been the historical performance of Bafna Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bafna-pharma-3739329",
        "imagepath": "",
        "date": "2025-12-01 23:26:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income.</p>\n<p>Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg..."
      },
      {
        "title": "Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3738625",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_buyers_3738625.png",
        "date": "2025-12-01 11:31:19",
        "description": "Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3733804",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3733804.png",
        "date": "2025-11-27 14:40:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3731172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3731172.png",
        "date": "2025-11-26 10:40:50",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 255,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Nov-2025",
      "details": "We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2025 as published in Business Standard and Makkal Kural on November 13 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
      "datetime": "11-Nov-2025",
      "details": "The Board of Directors of the Company in the Meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025",
      "datetime": "11-Nov-2025",
      "details": "The Board of Directors of the Compant in the meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company for the Quarter and Half Year ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Bafna Pharma. falling/rising?

2025-12-11 00:47:43

Recent Price Movement and Market Context

Bafna Pharmaceuticals has experienced a notable downturn over the past week, with its stock price falling by 7.68%, significantly underperforming the broader Sensex index, which declined by only 0.84% during the same period. This recent weakness contrasts sharply with the company’s impressive year-to-date gains of 83.92%, far outpacing the Sensex’s 8.00% rise. Over the last year, the stock has also delivered a robust 75.87% return, compared to the Sensex’s modest 3.53% increase. However, the one-month performance reveals a steep 26.85% decline, indicating a period of correction or profit-taking by investors.

Technical Indicators and Trading Patterns

The stock’s technical profile suggests a mixed outlook. ...

Bafna Pharma. Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-06 10:10:33

Bafna Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by strong stock returns but tempered by concerns over valuation and fundamental quality metrics.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses

2025-12-05 14:36:39

Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-03 13:35:44

Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit

2025-12-02 13:20:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment.

How has been the historical performance of Bafna Pharma.?

2025-12-01 23:26:00

Revenue and Operating Performance Trends

Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income.

Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg...

Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit

2025-12-01 11:31:19

Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-27 14:40:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-26 10:40:50

Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

14-Nov-2025 | Source : BSE

We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2025 as published in Business Standard and Makkal Kural on November 13 2025.

Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025

11-Nov-2025 | Source : BSE

The Board of Directors of the Company in the Meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Half Year ended September 30 2025.

Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025

11-Nov-2025 | Source : BSE

The Board of Directors of the Compant in the meeting held on November 11 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company for the Quarter and Half Year ended September 30 2025.